CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
56.99
-1.35 (-2.31%)
At close: Feb 25, 2026, 4:00 PM EST
56.10
-0.89 (-1.56%)
After-hours: Feb 25, 2026, 4:55 PM EST
CG Oncology Revenue
CG Oncology had revenue of $1.67M in the quarter ending September 30, 2025, with 3,774.42% growth. This brings the company's revenue in the last twelve months to $2.17M, up 217.84% year-over-year. In the year 2024, CG Oncology had annual revenue of $1.14M with 458.33% growth.
Revenue (ttm)
$2.17M
Revenue Growth
+217.84%
P/S Ratio
2,114.61
Revenue / Employee
$19,239
Employees
113
Market Cap
4.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.14M | 935.00K | 458.33% |
| Dec 31, 2023 | 204.00K | 13.00K | 6.81% |
| Dec 31, 2022 | 191.00K | -10.17M | -98.16% |
| Dec 31, 2021 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCGON News
- 2 days ago - CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 5 weeks ago - CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha
- 6 weeks ago - CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC - GlobeNewsWire
- 7 weeks ago - CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - CG Oncology Undervalued Going Into A Busy 2026 - Seeking Alpha
- 2 months ago - New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 3 months ago - CG Oncology Announces New Board Member and Board Transition - GlobeNewsWire